Thymosin Alpha-1 vs Palmitoyl Tetrapeptide-7
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Thymosin Alpha-1
Thymosin Alpha-1 is a peptide naturally produced by the thymus gland that plays a crucial role in immune system modulation. It is approved in over 35 countries for various conditions including hepatitis B and C.
Full details →Palmitoyl Tetrapeptide-7
Palmitoyl Tetrapeptide-7 is an anti-inflammatory peptide that reduces IL-6 secretion. Combined with Palmitoyl Tripeptide-1, it forms Matrixyl 3000, addressing both collagen production and inflammation.
Full details →Side-by-Side Comparison
| Aspect | Thymosin Alpha-1 | Palmitoyl Tetrapeptide-7 |
|---|---|---|
| Mechanism | Enhances T-cell function and maturation, stimulates dendritic cell activity, and modulates cytokine production. Promotes the differentiation of stem cells into mature T lymphocytes. | Suppresses interleukin-6 (IL-6) production, reducing inflammation that contributes to skin aging. The anti-inflammatory effect complements collagen-stimulating peptides. |
| Typical Dosage | Clinical dosing typically ranges from 1.6mg to 6.4mg administered subcutaneously 2-3 times weekly. Research protocols may vary. | Topical: Usually combined with Palmitoyl Tripeptide-1 at similar concentrations (2-4%) in the Matrixyl 3000 complex. |
| Administration | Subcutaneous injection. Often used in cycles or as part of comprehensive immune support protocols. | Topical application with other anti-aging actives. The palmitoyl group enhances delivery into the skin. |
| Side Effects | Generally well-tolerated. Rare side effects include injection site reactions, mild flu-like symptoms, and temporary fatigue. | Excellent tolerability profile. Anti-inflammatory properties may actually soothe sensitive skin. |
| Best For |